In an interview with pharmaphorum, Dion Warren, head of Takeda's European oncology business, said it is hoping to broaden its cancer portfolio. Reports surfaced last year suggesting the firm had ...

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology. In the first deal, Takeda will collaborate with ...

The move aims to strengthen Takeda's oncology pipeline. From the effective date of the agreement, the company will be responsible for all subsequent development activities. The company will pay ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...

Today, Takeda has three core indications of focus: oncology, neuroscience and what the company calls GI-squared, which encompasses gastrointestinal and inflammation conditions.

Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta ...

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic partnership with King Saud University Medical City (KSUMC) to advance ...